Summerset Group Holdings heads into the final quarter of 2026 trading near its weakest levels of the year, yet the most telling signal comes not from short sellers — who are barely present — but from the boardroom, where executives have been quietly adding shares on the way down.
The insider picture is the standout this week. Since March, a cluster of senior figures has made open-market purchases at progressively lower prices. The chairman picked up 5,000 shares at NZ$9.45 in March. The CFO bought 2,000 at NZ$9.43 the same day. The CEO added 2,500 at NZ$9.50. Then in late May, independent director Fiona Oliver bought again at NZ$7.70 — her second purchase in as many months, having paid NZ$8.43 in April. Against the stock's current NZ$7.60, every one of those buyers is underwater. The 90-day net insider position runs to just 3,250 shares at modest values, so this is not whale-scale accumulation. But the pattern — chairman, CEO, CFO and a director all buying with their own money into a falling stock — is the kind of alignment that tends to be worth noting.
The short side offers little drama. Short interest is negligible, and the borrow market is about as loose as it gets. Availability runs at roughly 1,570% of short interest — meaning lenders hold nearly 16 shares available for every one currently shorted. That places availability comfortably above even the 52-week floor of 701%. There is no squeeze pressure here, and no sign of bears building meaningful positions. Cost to borrow did spike briefly to around 32% on 9 September and 22% on 15 September — sharp, temporary moves that stand out against the usual sub-5% baseline and have since retreated to 2.6%. The spikes are worth flagging as evidence of episodic demand for borrows, though they did not persist. The stock's ORTEX short score has drifted lower over the past fortnight, from around 34 to just under 32, consistent with bears retreating rather than pressing.
The Street view is harder to lean on this week. The analyst consensus data carries a mean price target of NZ$12.76 — implying substantial upside from NZ$7.60 — but the figures date to late August and no recent target changes are in the record. Treat that implied upside as directional context rather than a live call. On valuation, the stock trades at a PE of roughly 7.3x and a price-to-book below 0.5x, both of which have compressed modestly over the past month. The dividend score ranks in the 95th percentile of the universe — high for a sector that has been paying down debt rather than distributions. EPS momentum, however, is weak: both the 30-day and 90-day readings rank near the bottom of the universe, in the 19th and 22nd percentiles respectively. Growth expectations remain positive on a forward basis, but the near-term earnings revision trend is working against sentiment.
The closest listed peer, RYM (Ryman Healthcare), managed a 1.8% gain on the week — a modest outperformance against Summerset's 4% decline. Ryman's own financial restructuring and recapitalisation have kept it in focus, so its relative strength this week may reflect stock-specific flows rather than a sector-wide read. Healthcare peers on the ASX, including RHC, also posted a positive week, up around 3.4%, which makes Summerset's underperformance harder to attribute solely to macro conditions.
The next scheduled earnings event falls on 26 November. The prior two results produced outsized single-day moves — up 8.3% and up 10.4% respectively — while the one before that barely moved the stock. Whether the insider accumulation at higher prices reflects confidence ahead of that print, or simply reflects long-term holders adding to positions at what they consider attractive multiples, is what the November update will start to clarify.
See the live data behind this article on ORTEX.
Open SUM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
